Hookipa Pharma Inc., a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, has entered into a clinical collaboration and supply agreement with Merck & Co., Inc., Kenilworth, NJ., USA to evaluate the combination of HB-200, a novel arenaviral immunotherapeutic, and Merck & Co., Inc., Kenilworth, NJ., USA’s anti-PD-1 therapy, Keytruda (pembrolizumab) as first-line treatment for patients with advanced head and neck squamous cell carcinoma (HNSCC...